Table 1.
Targeted therapy in metastatic colorectal cancer
| Study | No. of Patients | Study Type | Response Rate | Median TTP | Median PFS | Median OS | References |
|---|---|---|---|---|---|---|---|
| First-line Therapy | |||||||
| 5-FU/FA | 36 | Phase 2 | 17% | 5.2 mo | — | 13.8 mo | 20 |
| 5-FU/FA and Bevacizumaba | 35 | 40% (P = .029) | 9.0 mo (P = .005) | — | 21.5 mo | ||
| IFL | 411 | Phase 3 | 34.8% | — | 6.2 mo | 15.6 mo | 21 |
| IFL/Bevacizumab | 402 | 44.8% (P = .004) | — | 10.6 mo (P<.001) | 20.3 mo (P<.001) | ||
| FOLFOX-4 or XELOX | 701 | Phase 3 | 49% | — | 8.0 mo | 19.9 mo | 23 |
| FOLFOX-4 or XELOX with Bevacizumab | 699 | 47% (P = .31) | — | 9.4 mo (P = .002) | 21.3 mo (P = .08) | ||
| Second-line Therapy | |||||||
| FOLFOX-4 | 291 | Phase 3 | 8.6% | — | 4.7 mo | 10.8 mo | 26 |
| FOLFOX-4/Bevacizumab | 286 | 22.7% (P<.0001) | — | 7.3 mo (P<.0001) | 12.9 mo (P = .001) | ||
| Cetuximab | 111 | Phase 2 | 10.8% | 1.5 | — | 6.9 mo | 41 |
| Cetuximab/Irinotecan | 218 | 22.9% (P = .007) | 4.1 mo (P<.001) | — | 8.6 mo | ||
| BSC | 285 | Phase 2 | 0% | — | — | 4.6 mo | 45 |
| Cetuximab/BSC | 287 | 8% (P<.001) | — | — | 6.1 mo (P = .005) | ||
| BSC | 232 | Phase 3 | 0% | — | 1.8 mo | — | 48 |
| Panitumumab/BSC | 231 | 10% (P<.0001) | — | 2.0 mo (P<.0001) | — | ||
| Cetuximab/Bevacizumab | 40 | Phase 2 | 20% | 4.9 mo | — | 11.4 mo | 64 |
| Cetuximab/Bevacizumab/ Irinotecan | 43 | 37% | 7.3 mo | — | 14.5 mo | ||
Abbreviations: BSC, best supportive care; IFL, irinotecan, bolus 5-fluorouracil and folinic acid; OS, overall survival; TTP, time to progression; PFS, progression free survival.
a
Using bevacizumab at 5 mg/kg.